Abstract: The present invention relates to novel pyrrolidine derivative of formula (I), its geometrical isomers, its optically active forms as enantiomers, diastereomers, mixtures of these and its racemate forms, as well as salts thereof, wherein R1 is selected from the group comprising or consisting of H and C1–C6-alkyl, for the prevention and/or treatment of preterm labor, premature birth or dysmenorrhea
Type:
Grant
Filed:
July 4, 2003
Date of Patent:
October 3, 2006
Assignee:
Applied Research Systems ARS Holding N.V.
Abstract: The present invention concerns a use of a MHC class II ligand, such as CD4 and LAG-3, for the manufacture of a medicament for preventing or treating pathological conditions involving an antigen specific immune response, as well as the use of LAG-3 in cancer-immunotherapy. The invention also concerns a pharmaceutical composition comprising an effective amount of an antigen able to induce an antigen-specific immune response together with an effective amount of a MHC class II ligand wherein said MHC class II ligand is present as an adjuvant-like agent.
Type:
Grant
Filed:
January 10, 2002
Date of Patent:
September 19, 2006
Assignees:
Institut Gustave Roussy, Applied Research Systems ARS Holding, N.V.
Abstract: A method for identification of gene transcripts comprises the steps of: generating a set of raw sequences by sequencing of biological material; isolating ditags from the set of raw sequences; isolating tags from the ditags; determining abundance of the tags; and identifying the tags, the method providing a step of reducing the amount of sequencing errors by using a statistical model for sequencing errors.
Type:
Grant
Filed:
December 27, 2000
Date of Patent:
September 5, 2006
Assignee:
Applied Research Systems ARS Holdings N.V.
Abstract: The present invention relates ?-lactam derivatives, in particular for use as medicaments, as well as pharmaceutical formulations containing such ?-lactam derivatives. Said ?-lactam derivatives are useful in the treatment and/or prevention of asthma, hypertension, osteoporosis, sexual dysfunction and fertility disorders.
Type:
Application
Filed:
March 2, 2004
Publication date:
August 31, 2006
Applicant:
APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
Inventors:
Gian Araldi, Srinivasa Karra, Zhong Zhao, Nadia Brugger
Abstract: A device for reconstituting liquid for medical use by bringing together a first liquid medium contained in a first vessel in the form of a cartridge (3) and a second medium, such as a drug in solid form, contained in a second vessel in the form of a vial (7), the device (19) comprising means (41) for supporting the first and second vessels, and a movable operating member (50) for applying a force to cause the first liquid medium to be delivered at a controlled rate from the first vessel into the second vessel. The first and second vessels may be provided in a pack (70) having liquid transfer means in the form of a needle (10).
Type:
Grant
Filed:
December 10, 2001
Date of Patent:
July 18, 2006
Assignee:
Applied Research Systems ARS Holding N.V.
Inventors:
Grenville Arthur Robinson, Michael Anthony Hobbs, Martyn Omar Rowlands, John Richard Calvert
Abstract: The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulators include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.
Type:
Grant
Filed:
June 28, 2005
Date of Patent:
July 18, 2006
Assignee:
Applied Research Systems ARS Holding N.V.
Inventors:
Stephen Palmer, Sean McKenna, Mark Tepper, Aliza Eshkol, Michael C. MacNamee
Abstract: The present invention discloses open reading frames (ORFs) in human genome encoding for novel Preadipocyte factor-1-like polypeptides, and reagents related thereto including variants, mutants and fragments of said polypeptides, as well as ligands and antagonists directed against them. The invention provides methods for identifying and making these molecules, for preparing pharmaceutical compositions containing them, and for using them in the diagnosis, prevention and treatment of diseases.
Type:
Application
Filed:
December 23, 2003
Publication date:
July 13, 2006
Applicant:
Applied Research Systems ARS Holding N.V.
Abstract: The present invention relates to a novel method for preparing 21-hydroxy-6,19-oxidopro-gesterone (21OH-6OP) and/or its 21-acetate, 21-propionate, 21-hemisuccinate, 21-phosphate, 21-oleate derivatives. 21OH-6OP and its ester derivatives are antiglucocorticoids for the treatment or prophyl axis of diseases associated to an excess of glucocorticoids, in particular for treating Cushing's syndrome, iatrogenic hypercortisolism or depression.
Type:
Grant
Filed:
September 17, 2001
Date of Patent:
July 4, 2006
Assignee:
Applied Research System ARS Holding N.V.
Inventors:
Gerardo Burton, Carlos P. Lantos, Adriana Silvia Veleiro
Abstract: The present invention discloses open reading frames (ORFs) in human genome encoding for novel notch-like polypeptides, and reagents related thereto including variants, mutants and fragments of said polypeptides, as well as ligands and antagonists directed against them. The invention provides methods for identifying and making these molecules, for preparing pharmaceutical compositions containing them, and for using them in the diagnosis, prevention and treatment of diseases.
Type:
Application
Filed:
December 9, 2003
Publication date:
June 29, 2006
Applicant:
Applied Research Systems ARS Holding N.V.
Abstract: The present invention relates to the use of a TNF Receptor together with a steroid hormone to produce a pharmaceutical composition for the treatment of lethal bacterial and viral infections as well as autoimmune and inflammatory diseases. It also relates to said pharmaceutical compositions for the simultaneous separate or sequential use of its active ingredients for the above specified treatment. In particular, it relates to the use of TBP-1, together with dehydroepiandrosterone (DHEA) or its metabolites to produce a pharmaceutical composition for the treatment of septic shock.
Type:
Application
Filed:
February 13, 2006
Publication date:
June 29, 2006
Applicant:
Applied Research Systems ARS Holding N.V.
Abstract: A process for the purification of recombinant human Luteinizing Hormone (LH) from a sample of crude recombinant LH in the supernatant of CHO cells comprises the combined use of the ion-exchange chromatography and reverse phase HPLC. The ion-exchange chromatography and the reverse phase HPLC are performed twice and the final use of a gel permeation column allows the purification from any residual traces of contaminants. The specific bioactivity of the highly purified LH obtained from the process is particularly high, amounting to 25,000 IU/mg.
Type:
Grant
Filed:
January 22, 2001
Date of Patent:
May 30, 2006
Assignee:
Applied Research Systems ARS Holding N.V.
Inventors:
Gianfranco Paradisi, Mara Rossi, Laura Scaglia
Abstract: The present invention is related to novel 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) analogues, their use as antiglucocorticoids for the treatment and/or prophylaxis of disease associated to an excess of glucocorticoids. In particular, the invention relates to the use of novel 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) analogues for treating Cushing's syndrome, iatrogenic hypercortisolism or depression. Also the present invention is related to methods of preparing the novel 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) analogues.
Type:
Grant
Filed:
September 17, 2001
Date of Patent:
May 30, 2006
Assignee:
Applied Research Systems ARS Holding N.V.
Inventors:
Gerardo Burton, Carlos P. Lantos, Adriana Silvia Veleiro
Abstract: Recombinant human luteinizing hormone (LH) having a specific bioactivity of from 20,522 to 31,229 IU/mg and obtainable from a process for the purification of recombinant LH from a sample of crude recombinant LH in the supernatant of CHO cells which comprises the combined use of ion-exchange chromatography and reverse phase HPLC. The ion-exchange chromatography and the reverse phase HPLC are performed twice and the final use of a gel permeation column allows the purification from any residual traces of contaminants. The recombinant LH can be formulated into a pharmaceutical composition and used for treating a fertility disorder.
Type:
Application
Filed:
November 28, 2005
Publication date:
April 13, 2006
Applicant:
APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
Inventors:
Gianfranco Paradisi, Mara Rossi, Laura Scaglia
Abstract: The present invention discloses open reading frames (ORFs) in human genome encoding for novel chemokines-like polypeptides, and reagents related thereto including variants, mutants and fragments of said polypeptides, as well as ligands and antagonists directed against them. The invention provides methods for identifying and making these molecules, for preparing pharmaceutical compositions containing them, and for using them in the diagnosis, prevention and treatment of diseases.
Type:
Application
Filed:
September 29, 2003
Publication date:
April 13, 2006
Applicant:
Applied Research Systems ARS Holding N.V.
Inventors:
Mark Ibberson, Christine Power, Achim Frauenschuh
Abstract: The present invention is related to new substituted pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of neurodegenerative disorders, diseases associated with polygultamine tracts, epilepsy, ischemia, infertility, cardiovascular disorders renal hypoxia, hepatitis and AIDS. Said pyrrolidine derivatives display a modulatory and most notably a down-regulating-up to an inhibitory-activity with respect to the cellular death agonist Bax and/or the activation pathways leading to Bax and allows therefore to block the release of cytochrome (c).
Type:
Grant
Filed:
March 20, 2001
Date of Patent:
March 28, 2006
Assignee:
Applied Research Systems ARS Holding N.V.
Inventors:
Serge Halazy, Anna Quattropani, Agnes Bombrun, Mattias Schwarz, Russel Thomas, Anthony Baxter
Abstract: The present invention relates to the use of a TNF Receptor together with a steroid hormone to produce a pharmaceutical composition for the treatment of lethal bacterial and viral infections as well as autoimmune and inflammatory diseases. It also relates to said pharmaceutical compositions for the simultaneous, separate or sequential use of its active ingredients for the above specified treatment. In particular, it relates to the use of TBP-1 together with dehydroepiandrosterone (DHEA) or its metabolites to produce a pharmaceutical composition for the treatment of septic shock.
Type:
Grant
Filed:
October 13, 2000
Date of Patent:
March 14, 2006
Assignee:
Applied Research Systems ARS Holding N.V.
Abstract: The present invention relates to the use of recombinant IFN-beta for the production of a medicament for the treatment of HCV infection by subcutaneous administration to patients of Asian race, which failed to respond to a previous treatment with interferon-alpha, is herein reported. According to a preferred embodiment of the invention, this treatment can be better and further focused to those patients which after at least 4 weeks of initial treatment with IFN-beta show HCV RNA clearance.
Type:
Application
Filed:
May 28, 2003
Publication date:
February 9, 2006
Applicant:
Applied Research Systems ARS Holding N.V.
Inventors:
Ian Parsons, Theodor Wee Tit Gin, Birgit Maschek
Abstract: The invention relate to an automated method for identifying related biomolecular sequences having defined features of interest from databases, the databases comprising at least a first and a second set of sequences, each set being derived from a different type of organism, comprising the steps of: a) establishing from the first set of sequences a non-redundant list of query sequences having the defined features of interest (first family members), using a database search program; b) performing sequence alignments with the first family members in a second set of sequences derived from a second type of organism, using a database search program and a preset similarity threshold, giving a list of second family members: c) establishing a two dimensional matrix displaying the first and second family members and their respective similarity values resulting from step (b), optionally displaying only those second family members having similarity values exceeding a preset threshold value; d) selecting from the matrix tho
Type:
Grant
Filed:
November 16, 2000
Date of Patent:
February 7, 2006
Assignee:
Applied Research Systems ARS Holding N.V.
Inventors:
Jacques Colinge, Rob Hooft Van Huijsduijnen